New insider activity at Guardant Health ( (GH) ) has taken place on April 7, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Guardant Health’s Chief People Officer, Terilyn J. Monroe, recently sold 3,832 shares of the company’s stock in a transaction valued at $355,149. This insider sale highlights a notable move by a key executive, drawing investor attention to trading activity within Guardant Health’s leadership team.
Recent Updates on GH stock
Guardant Health shares saw renewed attention as Citi put the stock on a short-term catalyst watch, citing upside to Q1 estimates from higher selling prices and noting the valuation multiple has already pulled back. In contrast, Evercore trimmed its outlook in a broader med-tech preview, reflecting a more cautious stance on the sector rather than company-specific disappointment.
Wells Fargo highlighted the recent pullback as an opportunity, arguing that several potential catalysts are not yet reflected in Guardant’s long-term guidance, including possible ACS guideline changes, expanded reimbursement coverage, and upcoming product launches. Separately, positive fundamental news included InfinityAI-derived real-world evidence supporting a new ENHERTU approval in Japan and a data partnership with Verana Health, both underscoring Guardant’s growing role in oncology data and AI-driven insights.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
The score is held back primarily by weak financial performance (large losses, ongoing cash burn, and balance-sheet strain with negative equity and higher debt). Offsetting this, the latest earnings call was constructive with strong 2026 growth guidance and improving cash burn trajectory, while technical signals are mixed-to-neutral and valuation remains challenged due to losses and no dividend support.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
YTD Price Performance: -12.22%
Average Trading Volume: 1,943,600
Technical Sentiment Signal: Buy
Current Market Cap: $11.76B